What is Starget Pharma?
Starget Pharma is an early-stage clinical company dedicated to advancing precision oncology. The company is focused on developing a novel class of Smart Targeted Radioligands designed to treat hard-to-heal cancers. This approach aims to deliver highly accurate therapeutic interventions directly to cancer cells, minimizing damage to surrounding healthy tissues and improving patient outcomes.
How much funding has Starget Pharma raised?
Starget Pharma has raised a total of $21.5M across 2 funding rounds:
Other Financing Round
$5.1M
Private Equity
$16.4M
Other Financing Round (2024): $5.1M with participation from The Cancer Focus Fund
Private Equity (2026): $16.4M, investors not publicly disclosed
Key Investors in Starget Pharma
The Cancer Focus Fund
The Cancer Focus Fund is an oncology-focused investment fund established in collaboration with The University of Texas MD Anderson Cancer Center, specializing in precision investing in new cancer therapies.
What's next for Starget Pharma?
With this substantial backing, Starget Pharma is poised to accelerate its clinical development pipeline and further its research into targeted radioligand therapies. The strategic investment suggests confidence from investors in the company's technology and its potential to address unmet needs in oncology. Future endeavors will likely focus on advancing preclinical and clinical trials, potentially expanding the company's therapeutic reach and solidifying its position in the precision medicine landscape.
See full Starget Pharma company page
